Pancragen
Also known as: Lys-Glu-Asp, Khavinson pancreas peptide, Pancreatic bioregulator
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Half-Life
Short (minutes); sustained gene-regulatory effects
Route
SubQ, Oral
Category
Anti-Aging & Longevity
Studies
5 references
Key Benefits
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
Mechanism of Action
Pancragen's tripeptide Lys-Glu-Asp acts as a gene expression modulator in pancreatic cells. In beta cells, it supports normalization of insulin gene expression and secretory function. In exocrine pancreatic tissue, it promotes enzyme synthesis and cellular regeneration. By interacting with chromatin in pancreatic cells, it restores more youthful patterns of protein synthesis and reduces apoptosis driven by metabolic stress or aging.
Dosing Protocols
Standard Khavinson Protocol
- Dose
- 10 mg per day
- Frequency
- Daily for 10–30 days
- Timing
- Subcutaneous injection or oral (enteric-coated)
- Cycle
- 10–30 day course, repeated 2–4x per year
Often included in metabolic and anti-aging Khavinson protocols. Research use only.
Calculate your draw volume
Enter your vial size and BAC water to get exact injection volumes
Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
Contraindications
Not FDA approved. Not a substitute for insulin therapy or standard diabetes medications. Medical supervision required for any diagnosed pancreatic condition.
Storage
Store at 2–8°C. Protect from moisture and light.
Clinical Research
- 1.Effects of pancragen on the differentiation of pancreatic cells during their ageing
Khavinson VKh, Durnova AO, Polyakova VO, Tolibova GH, Linkova NS, Kvetnoy IM et al. · Bulletin of experimental biology and medicine · 2013PubMed Verified
- 2.Peptides tissue-specifically stimulate cell differentiation during their aging
Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM · Bulletin of experimental biology and medicine · 2012PubMed Verified
- 3.Prospects of using pancragen for correction of metabolic disorders in elderly people
Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA, Bondarenko EV · Bulletin of experimental biology and medicine · 2011PubMed Verified
- 4.Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide
Khavinson VKh, Gapparov MM, Sharanova NE, Vasilyev AV, Ryzhak GA · Bulletin of experimental biology and medicine · 2010PubMed Verified
- 5.Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus
Khavinson VKh, Gavrisheva NA, Malinin VV, Chefu SG, Trofimov EL · Bulletin of experimental biology and medicine · 2007PubMed Verified
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice. Many compounds listed are research chemicals not approved for human use. Always consult a qualified healthcare professional before starting any protocol.
Was this page helpful?
Launching soon
Build and track your protocol in Staqk
Log doses, track timing, monitor biomarkers, and manage every compound in your stack — all in one place.